Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16), doxorubicin, and mitoxantrone, are among the most effective anticancer drugs in clinical use. However, Top2-based chemotherapy has been associated with higher incidences of secondary malignancies, notably the development of acute myeloid leukemia in VP-16-treated patients. This association is suggestive of a link between carcinogenesis and Top2-mediated DNA damage. We show here that VP-16-induced carcinogenesis involves mainly the ␤ rather than the ␣ isozyme of Top2. In a mouse skin carcinogenesis model, the incidence of VP-16-induced melanomas in the skin of 7,12-dimethylbenz[a]anthracene-treated mice is found to be significantly higher in TOP2␤ ؉ than in skin-specific top2␤-knockout mice. Furthermore, VP-16-induced DNA sequence rearrangements and double-strand breaks (DSBs) are found to be Top2␤-dependent and preventable by cotreatment with a proteasome inhibitor, suggesting the importance of proteasomal degradation of the Top2␤-DNA cleavage complexes in VP-16-induced DNA sequence rearrangements. VP-16 cytotoxicity in transformed cells expressing both Top2 isozymes is, however, found to be primarily Top2␣-dependent. These results point to the importance of developing Top2␣-specific anticancer drugs for effective chemotherapy without the development of treatment-related secondary malignancies.
A
nticancer drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16), doxorubicin, and mitoxantrone, are often referred to as Top2 poisons and are among the most effective and widely used anticancer drugs in the clinic. However, life-threatening toxic side effects, including drug-induced secondary malignancies, have been noted in patients receiving Top2-based chemotherapy. An association between infant leukemia and in utero exposure to Top2 poisons has also been reported (reviewed in refs. [1] [2] [3] . In all cases, the molecular basis underlying carcinogenesis in Top2-based chemotherapy is unclear.
Clinical evidence for a direct link between VP-16 treatment and treatment-related acute myeloid leukemia (t-AML) is particularly strong (1) (2) (3) . VP-16-induced t-AML is frequently associated with balanced translocations between the mixed lineage leukemia (MLL) gene on chromosome 11q23 and Ͼ50 partner genes (the MLL gene is also known as ALL-1, hTRX, or HRX) (4) (5) (6) (7) . These rearrangements, as well as those found in infant leukemia, cluster within a well characterized 8.3-kb breakpoint cluster region (bcr) (8) (9) (10) (11) (12) (13) (14) (15) (16) . The bcr of MLL is AT-rich and contains Alu sequences, putative recognition sites of Top2-mediated DNA cleavage, and chromosome scaffold/matrix attachment regions (SAR/MAR) (5, (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . There is substantial evidence that chromosome 11q23 translocations in t-AML and infant leukemia are a consequence of drug-induced formation of double-strand breaks (DSBs) (6) (7) (8) (9) . VP-16 is known to induce DSBs by the formation of a Top2-DNA covalent complex termed the cleavage or cleavable complexes (reviewed in refs. 18 and 19) , and mapping of VP-16-induced DSBs to the bcr of the MLL gene has led to the suggestion of a direct link between these DSBs and MLL gene translocations (8, (12) (13) (14) (15) 20) . However, other studies have also pointed to the involvement of apoptotic nucleases in VP-16-induced DSBs within the bcr of the MLL gene (21) (22) (23) (24) (25) (26) .
There are two human Top2 isozymes, Top2␣ and Top2␤ (27, 28) , and VP-16 is known to induce both Top2␣ and Top2␤ DNA cleavage complexes (29, 30) . The two isozymes share Ϸ70% sequence similarity but are regulated very differently during cell growth: the ␣ isozyme is a proliferation marker and is greatly elevated in tumor cells, whereas the ␤ isozyme is present in proliferating as well as postmitotic cells (31) (32) (33) (34) . Top2␣ has been suggested to function in cell cycle events such as DNA replication and chromosome segregation (35) (36) (37) (38) , and Top2␤ has been implicated in transcription (34, 39, 40) . It has been unclear, however, whether these two isozymes play different roles in tumor-cell killing and in the development of secondary malignancies during the course of Top2-based chemotherapy.
Previous studies in a mouse skin carcinogenesis model have demonstrated that VP-16 induces carcinogenesis, and it has been suggested that the drug acts as a stage I (convertogenic) tumor promoter (41) . In the present study, we have used skin-specific top2␤-knockout mice to test the possibility that the Top2␣ and Top2␤ isozymes have different roles in the development of secondary malignancies and in tumor-cell killing. Our results suggest that the ␤ isozyme is primarily responsible for VP-16-induced carcinogenesis in this model. Furthermore, in cell-culture models, VP-16-induced DNA sequence rearrangements and DSBs are also found to be primarily Top2␤-dependent. By contrast, VP-16 cytotoxicity in tumor cells appears to be primarily Top2␣-dependent. These results suggest that the two Top2 isozymes play distinct roles in Top2-based chemotherapy and point to the importance of developing Top2␣ isozyme-specific drugs for cancer chemotherapy without a high risk of treatment-related secondary malignancies.
Results

VP-16-Induced Melanomas in the Skin of 7,12-Dimethylbenz[a]-
anthracene (DMBA)-Treated Mice Are Top2␤-Dependent. To evaluate the role of Top2␤ in VP-16-induced carcinogenesis, skin-specific top2␤-knockout mice (K14-Cre top2␤ flox2/flox2 ) and TOP2␤ ϩ controls (top2␤ flox2/flox2 , top2␤ ϩ/flox2 , and K14-Cre top2␤ ϩ/flox2 ) were generated. The top2␤ flox2 allele contains two loxP sites flanking a DNA segment encoding the active-site tyrosine region of Top2␤. This allele expresses wild-type Top2␤, but is converted to a null allele, top2␤ ⌬2 , upon exposure to Cre recombinase expressed from a transgene (34) , in the present case, one under the control of the skin-specific promoter K14 (see Materials and Methods). As shown in Fig. 1A , Top2␤ is absent from both the epidermis (Upper) and hair follicles (Lower) of K14-Cre top2␤ flox2/flox2 mice (to be referred to hereafter as the TOP2␤ Ϫ mice), as evidenced by the absence of Top2␤ immunostaining in DAPI-positive nuclei (see also Fig. 1B for genotyping examples). Cre-mediated deletion of the floxed top2␤ locus is further evidenced by the appearance of the PCR product corresponding to the top2␤ ⌬2 allele (to be referred to hereafter as the top2␤ Ϫ allele; see lanes 2 and 3 in Fig. 1B ).
Age-matched 7-week-old mice were used for skin carcinogenesis studies. Both TOP2␤ ϩ and TOP2␤ Ϫ mice received a single application of DMBA, followed by various treatments (see the six treatment groups in Materials and Methods). Under the treatment conditions, these mice developed skin melanomas (Fig. 1C) . Papillomas, which appeared at an Ϸ80-fold lower frequency (data not shown), were not included in the analysis. Histology of a typical melanoma in the mouse skin is shown in Fig. 1D Upper. The expansive dark-brown area showing aggregation of pigmented cells (melanin-expressing melanocytes) is indicative of melanoma. Immunohistochemical analysis of the tumor with mouse melanoma mixture antibody also confirmed the presence of melanoma (Fig.  1D Lower) .
The number of melanomas in the skin of each treated mouse was recorded and all data are summarized in Fig. 2A . The average number of melanomas per mouse in various treatment groups is also plotted for each treatment group (Fig. 2 B and C) . As shown in Fig. 2B , (open bars), VP-16 treatment of DMBA-initiated TOP2␤ ϩ mice (see groups 2 and 3 for 10 mol ϫ 5 applications and 20 mol ϫ 3 applications of VP-16, respectively) show an increase in the average number of melanomas per mouse (by 10% and 60%, respectively) relative to treatment with DMSO alone (group 1). Strikingly, VP-16 treatment of DMBA-initiated TOP2␤ Ϫ mice decreases, rather than increases, the average number of melanomas per mouse by 50% and 15%, respectively, in groups 2 and 3, relative to the DMSO-treated group 1 controls (Fig. 2B, filled bars) . This decrease probably reflects a combination of two factors: the absence of VP-16-induced melanomas, owing to the absence of Top2␤, and the antitumor activity of VP-16 (which is largely Top2␣-dependent, to be discussed later).
If the above interpretation is correct, increasing the number of VP-16 applications should further reduce the number of 
melanomas in TOP2␤
Ϫ mice. Indeed, as shown in Fig. 2C (filled bars), increasing the number of VP-16 applications (5 mol per application) from 5 (group 5) to 10 (group 6) significantly decreases the average number of melanomas in the skin of TOP2␤ Ϫ mice (a decrease of 30% and 87%, respectively, for the two groups, relative to group 1). As a positive control, DMBAtreated TOP2␤ ϩ and TOP2␤ Ϫ mice were also treated with TPA (see Fig. 2B , group 4). As expected, TPA treatment of the TOP2␤ ϩ mice greatly increased the average number of melanomas per mouse (by 130%) relative to DMSO treatment (Fig.  2B, open bars) . In contrast to VP-16 treatment, exposure to TPA causes a similar degree of increase (150%) in skin melanoma in TOP2␤ Ϫ mice (Fig. 2B, filled bars) .
The effect of Top2␤ on the number of VP-16-induced melanomas in mouse skin is more evident by examining the ratio of the average number of melanomas per mouse in TOP2␤ ϩ versus that in TOP2␤ Ϫ mice. For the VP-16-treated groups, the ratios are 2.0 (group 5), 2.8 (group 3), 3.3 (group 2), and 13 (group 6). By contrast, the ratios are 1.5 and 1.3, respectively, for groups 1 (vehicle control) and 4 (TPA treatment). The differences in the numbers of VP-16-induced melanomas in TOP2␤ ϩ and TOP2␤ Ϫ mice are statistically significant (P Ͻ 0.05, see groups marked by * in The neutral comet assay, which measures the amount of fragmented chromosomal DNA from gently lysed cells and has been extensively used in quantifying chromosomal DSBs, was also used to assess the role of the Top2␤ isozyme in VP-16-induced chromosome breakage. As shown in Fig. 3C , in wild-type TOP2␤ ϩ/ϩ MEFs, VP-16 induces a significant increase (130%, P ϭ 5 ϫ 10 Ϫ8 ) in fragmented DNA, relative to treatment with the DMSO solvent alone. By contrast, in top2␤ Ϫ/Ϫ MEFs, the corresponding increment of Ϸ30% is statistically insignificant (P ϭ 0.31). Repeating the experiment by using SV40-transformed TOP2␤ ϩ/ϩ and top2␤ (30) . In a DNA cleavage assay (42) using equal amounts of purified recombinant human Top2␣ and Top2␤ isozymes, about equal amounts of Top2␣ and Top2␤ cleavage complexes were observed at various concentrations of VP-16 (Fig.  4A) . A band-depletion assay measuring the reduction in the amounts of Top2␣ and Top2␤ not covalently trapped on DNA (43), after a 15-min VP-16 treatment, also indicated that in SV40-transformed wild-type TOP2␤ ϩ/ϩ MEFs, both Top2␣ and Top2␤ bands are depleted to similar extents (Fig. 4B Upper; see Fig. 4B Lower for quantification).
Previous studies (43, 44) have demonstrated, however, that in VP-16-treated cells, the Top2␤ isozyme covalently trapped on DNA is preferentially degraded over the DNA-trapped Top2␣ isozyme through a proteasome-dependent pathway. It has been suggested that this preferential degradation of Top2␤-DNA cleavage complexes is a key factor in VP-16-induced DSB formation. In support of this notion, cotreatment with the proteasome inhibitor MG132 is found to abolish DSB induction by VP-16, as evidenced by results of neutral comet assays (data not shown) (44) . Cotreatment with MG132 is also found to reduce VP-16-induced plasmid Primary TOP2␤ ϩ/ϩ and top2␤ Ϫ/Ϫ MEFs, denoted by ϩ/ϩ and Ϫ/Ϫ, respectively, were treated with VP-16 (250 M, 2 h), and cell lysates were immunoblotted after gel electrophoresis by using anti-␥-H2AX as well as anti-␣-tubulin antibody (the latter for loading assessment). The expression levels of Top2␣ and Top2␤ in primary TOP2␤ ϩ/ϩ and top2␤ Ϫ/Ϫ MEFs were similarly assessed (Inset). (C) VP-16 induces DNA DSBs as measured by the neutral comet assay. Primary TOP2␤ ϩ/ϩ and top2␤ Ϫ/Ϫ MEFs (denoted, respectively, by ϩ/ϩ and Ϫ/Ϫ in the figure) were treated with VP-16 (250 M, 1.5 h). The neutral comet assay was then performed as described in ref. 45 (Left) , and the average tail moments were quantified and plotted (Right) (error bars indicate SEM; * , P Ͻ 0.001 in comparing the ϩ/ϩ and Ϫ/Ϫ data).
integration in top2␤
ϩ/Ϫ MEFs by Ϸ3-fold (P ϭ 0.01; see Fig. 3A and compare the last two sets of open bars). Thus, it appears that the preferential role of the Top2␤ isozyme in VP-16-induced DSBs and DNA sequence rearrangements is owing to its greater sensitivity to proteasome-mediated degradation when covalently trapped on DNA. Indeed, in SV40-transformed wild-type TOP2 MEFs treated with VP-16, Top2␤ is found to be preferentially degraded relative to Top2␣ in a proteasome-dependent manner (Fig. 4C ).
Top2␤ Contributes Minimally to VP-16 Cytotoxicity in Transformed
Cells. The above studies suggest that Top2␤ is primarily responsible for VP-16-induced DSBs and DNA sequence rearrangements. To test whether Top2␤ is also important for VP-16 cytotoxicity, we determined in triplicate the IC 50 of VP-16 for two pairs of transformed top2␤-knockout/knockdown cells by using a colorimetric assay based on cleavage of the tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by mitochondrial dehydrogenase from viable cells. The IC 50 values of VP-16 are not significantly different for top2␤ ϩ/Ϫ and top2␤ Ϫ/Ϫ MEFs (0.038 Ϯ 0.007 vs. 0.040 Ϯ 0.006 M; P ϭ 0.43, t test). Furthermore, in PC12 cells expressing top2␤ short hairpin RNA (shRNA), whereas the level of Top2␤, but not Top2␣, is much reduced (by Ϸ90%) relative to the same cells expressing the control shRNA. IC 50 values of VP-16 for the same pair of samples are not significantly different (1.6 Ϯ 0.1 and 1.9 Ϯ 0.1 M, respectively; P ϭ 0.19, t test). These results indicate that whereas Top2␤ rather than Top2␣ plays a major role in VP-16-induced carcinogenesis, the opposite is true in terms of VP-16 cytotoxicity.
Discussion
Previous studies have demonstrated that VP-16 induces papillomas on the skin of DMBA-treated mice in a classical two-stage carcinogenesis model; furthermore, switching the order of VP-16 and DMBA applications has no effect on papilloma incidence, indicating that the drug behaves as a stage I (convertogenic) tumor promoter, presumably through its induction of DNA sequence rearrangements (41) . In the present study, we have used skinspecific top2␤-knockout mice to evaluate the roles of the two isozymes of DNA, Top2␣ and Top2␤, in VP-16-induced carcinogenesis. Melanomas, rather than papillomas, are the main tumor type detected in the mouse skin in the present study, however, plausibly because of genetic background differences of the mouse strains used: previous studies used albino mice that probably produce no visible melanoma because of a lack of melanin expression in their skin, whereas mice used in the present study have a mixed genetic background, including 129SvEv (Ͼ75%), various degrees of BALB/c and C57BL/6, and express melanin in the skin. VP-16 is shown to induce 2-to 13-fold more melanomas, depending on the dose and schedule of VP-16 treatment, in the skin of DMBA-treated TOP2␤ ϩ mice than in that of similarly treated skin-specific top2␤-knockout mice. By contrast, the classical tumor promoter, TPA, induces about the same number of skin melanomas in DMBA-treated mice whether Top2␤ is expressed in the skin or not. These results suggest that it is the Top2␤ isozyme that plays a predominant role in VP-16-induced carcinogenesis.
The above conclusion is further supported by studies in tissue culture models. By using a plasmid integration assay to monitor DNA sequence rearrangements, VP-16-stimulated integration of plasmid DNA is shown to be Top2␤-dependent: stimulation of integration frequency by VP-16 is much more significant in SV40-transformed MEFs derived from top2␤ ϩ/Ϫ mice, which express Top2␤, than in SV40-transformed MEFs derived from top2␤ Ϫ/Ϫ mice, which do not. Furthermore, the proteasome inhibitor MG132 blocks VP-16-stimulated plasmid integration, suggesting that VP-16-induced DNA sequence rearrangements involve the proteasome pathway. The last result is consistent with that of a recent study implicating the involvement of the proteasome path- way in processing VP-16-induced Top2␤-DNA covalent complexes into DSBs (44) .
The predominant role of the Top2␤ isozyme in mediating VP-16-induced carcinogenesis and DNA sequence rearrangements can be attributed to its involvement in DSB formation upon VP-16 treatment. Neutral comet assay indicates that VP-16-induced DSBs are Top2␤-dependent in both primary and SV40-transformed MEFs. Furthermore, the predominant role of the Top2␤ isozyme in VP-16-mediated DSB formation is likely the result of a greater sensitivity of the DNA cleavage complexes of Top2␤, relative to that of Top2␣, in proteasome-mediated degradation. Whereas the two isozymes are comparable in their ability to form covalent complexes, the Top2␤-concealed DNA breaks in the covalent complexes appear to be more easily converted to DSBs by the proteasome degradation pathway (44) .
Based on these and other results, a model for the role of Top2␤ in VP-16-induced DSBs, DNA sequence rearrangements, and carcinogenesis is proposed (see Fig. 5 for a schematic) . In this model, VP-16 stabilizes reversible Top2␤-DNA cleavage complexes, which are converted into nonreversible Top2␤-DNA covalent complexes, in part through transcriptional collisions (43). The nonreversible covalent complexes then undergo proteasomal degradation, baring the hidden DSBs in them; processing of these DSBs through nonhomologous end-joining finally leads to DNA sequence rearrangements and carcinogenesis. It is unclear why the DNA cleavage complexes of Top2␤ are more sensitive to proteasome-mediated degradation than their Top2␣ counterparts. Because proteasomal degradation of Top2 cleavage complexes is partially transcription-dependent (43) , however, the preferential sensitivity of the Top2␤ complexes to proteasomal degradation might be related to the preferential involvement of Top2␤ in transcription (39, 40) . Further studies are necessary to establish the molecular pathways in processing the Top2-DNA covalent complexes.
Whereas Top2␤, rather than Top2␣, is shown to have a predominant role in VP-16-induced carcinogenesis, our studies of Top2␤-knockout and knockdown cells suggest that the opposite is the case in VP-16 cytotoxicity against transformed cells. The importance of Top2␣ in VP-16 cytotoxicity is consistent with results from previous studies that the TOP2␣ gene is mutated in cell lines selected for lower levels of resistance to Top2 drugs, and the TOP2␤ gene is mutated only in top2␣ mutant cells selected for higher levels of resistance to Top2 drugs (45, 46) . It has been suggested that the collision between the replication forks and Top2 cleavage complexes plays a major role in VP-16 cytotoxicity (47); consequently, the predominant role of Top2␣ in DNA replication may lead to more frequent collisions between this isozyme and the replication fork, and hence its higher cytotoxicity.
There are several important clinical implications of our findings. First, Top2-targeting drugs such as VP-16 are known to be associated with the development of secondary malignancies, such as t-AML from MLL gene translocations (1-3) . The predominant role of the Top2␤ isozyme in VP-16-induced DNA sequence rearrangements and carcinogenesis suggests that the action of VP-16 on Top2␤ is the major reason for the development of secondary malignancy in patients receiving Top2-based chemotherapy. Accordingly, the development of Top2␣ isozyme-specific anticancer drugs may offer the clinical advantage of reducing secondary malignancies. Second, our findings suggest that chemotherapy with anticancer drugs specific to Top2␣ may also reduce other types of tissue toxicity, because Top2␤, and not Top2␣, is present in nonproliferating tissues such as the adult heart. Third, based on the proposed mechanism outlined in Fig. 5 , other strategies are conceivable for preventing the development of secondary malignancies associated with Top2-based chemotherapy. Cotreatment with the proteasome inhibitor bortezomib, for example, is predicted to prevent proteasomal processing of Top2␤-DNA covalent complexes into DSBs and may thus prevent the development of malignancies such as t-AML in patients receiving Top2-based chemotherapy. Proteasome inhibitors may also increase cytotoxicity of Top2 drugs and hence enhance treatment efficacy, because unprocessed Top2␤-DNA covalent complexes are expected to contribute to cytotoxicity.
Materials and Methods
Mouse Strains. Skin-specific deletion within the floxed top2␤ allele is achieved by crossing the top2␤ flox2 lines (34) with mice expressing Cre recombinase from the keratin 14 promoter (kindly provided by A. P. McMahon, Harvard University). The K14-Cre transgenic mouse line expresses Cre in keratinocytes of the epidermis as well as hair follicles during prenatal and postnatal development (48, 49) . Mice with the genotype K14-Cre top2␤ f lox2/f lox2 , K14-Cre top2␤ ϩ/flox2 , top2␤ flox2/flox2 , and top2␤ ϩ/flox2 were generated and used in this study; with the exception of K14-Cre top2␤ flox2/flox2 mice, which specifically lack Top2␤ in skin cells, all of the others are phenotypically TOP2␤ ϩ in all tissues. The K14-Cre top2␤ flox2/flox2 skin-specific top2␤-knockout mice exhibit a normal lifespan and show no skin abnormality other than cyclic alopecia (data not shown). Genotyping of the various alleles was done as described (in refs. 34 and 49).
Carcinogenesis Assay with a Mouse Skin Model. Seven-week-old skin-specific top2␤-knockout mice and their TOP2␤ ϩ controls were used. The back of each mouse was shaved 2 days before treatment. The tumor initiator DMBA (1 mol in 100 l of DMSO) was applied once in the first week, and then various treatments (2 applications per week) were applied for six groups of animals: group 1, DMSO (100 l), 5 applications; group 2, VP-16 ( l of DMSO), 10 applications. Mice were examined every week for appearance of melanomas on their skins. The number of melanomas visibly notable was scored at the end of the 16th week. The average numbers of tumors induced in different treatment groups were compared by using Student's t test.
Histochemical and Immunohistochemical Analyses. Immunohistochemical analysis and melanin bleaching of mouse skin sections were performed as described (50, 51) . Mouse melanoma mixture antibody (Abcam, Cambridge, MA), rabbit anti-Top2␤ antibody (Santa Cruz Biotechnology, Santa Cruz, CA), and Cy3-or Cy2-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA) were used in these experiments.
Cells. Primary MEFs were isolated from day 13.5 TOP2␤ ϩ/ϩ , top2␤ ϩ/⌬2 and top2␤ ⌬2/⌬2 mouse embryos, as described in ref. 44 , and SV40-transformed MEFs were obtained by transformation with pAN2 DNA (44) . PC12 cells were first clonally selected and then used to generate top2␤-shRNA and control-shRNA knockdown cells. A rat TOP2␤-shRNA sequence (5Ј-GCCCCCGT-TATATCTTCAC-3Ј) was generated based on partial rat TOP2␤ cDNA sequence (GenBank accession no. D14046). Duplex DNA of the sequence (5Ј-TGCCCCCGTTATATCTTCACTTCAA-GAGAGTGAAGATATAACGGGGGCTTTTTC-3Ј) was made and cloned into the LentiLox 3.7 vector (obtained from L. van Parijs, Massachusetts Institute of Technology, Cambridge, MA). The control-shRNA sequence (5Ј-GCGCGCGTTAAATCT-TCAC-3Ј) was created by altering three nucleotides in the rat TOP2␤-shRNA sequence (underlined), and duplex DNA of the sequence (5Ј-TGCGCGCGTTAAATCTTCACTTCAAGA-GAGTGAAGATTTAACGCGCGCTTTTTC-3Ј) was cloned into the LentiLox 3.7 vector. The shRNA-expressing vectors were then inserted with the phosphoglycerate kinase (PGK)-driven Neo r gene. Lentiviral stocks were prepared and virus-infected PC12 cells were selected from 2-week-old cultures in the presence of 700 g/ml G418. Single colonies were isolated and characterized and cultured in a 37°C incubator with 5% CO 2 , in RPMI medium 1640 supplemented with 10% horse serum, 5% FetalPlex animal serum complex (Gemini Bio-Products, West Sacramento, CA), 2 mM L-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin in flasks coated with collagen type I (BD Biosciences, San Jose, CA).
Plasmid Integration Assay. Assays with transformed MEFs were performed as described in ref. 26 . VP-16 was added at the time of transfection, and where indicated, the proteasome inhibitor MG132 (2 M) was added 30 min before and during transfection. Integration frequencies were calculated as the ratios of the numbers of blasticidin-resistant colonies and surviving cells.
